GENETIC MARKERS FOR PREDICTING SENSITIVITY TO THERAPY Russian patent published in 2023 - IPC C12Q1/686 C12Q1/6827 C12Q1/6874 A61K31/167 A61P9/00 

FIELD: biotechnology; pharmacogenomics.

SUBSTANCE: invention relates to the selection of an HDL-increasing agent suitable for treating a patient with a certain genotype, and can be used in medicine for personalized therapy with CETP inhibitors. The following has been proposed: increase in high-density lipoprotein (HDL) levels by administering of an effective amount of an HDL-raising agent, namely dalcetrapib, torcetrapib, anacetrapib, evacetrapib, BAY 60-5521, DEZ-001, ATH-03, DRL-17822 or DLBS-1449 by a subject having one or more of the following improved response genotypes: rs1967309/AA, rs12595857/GG, rs111590482/AG, rs111590482/GG, rs12935810/GG, rs17136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8061182/AA и rs11647828/GG.

EFFECT: invention predicts the increased probability that treatment with an HDL-increasing agent, in particular a CETP inhibitor, will be beneficial for patients with cardiovascular disorders based on the results of genotyping patients when certain forms of SNP are identified in them.

14 cl, 8 dwg, 9 tbl, 1 ex